Early mortality of alcoholic hepatitis: A review of data from placebo-controlled clinical trials

Chao-Hui Yu, Cheng-Fu Xu, Hua Ye, Lan Li, You-Ming Li

Abstract

AIM: To investigate the early mortality of placebo-treated alcoholic hepatitis patients.

METHODS: Mortality data about alcoholic hepatitis patients who participated in randomized placebo-controlled trials were searched from PubMed, EMBASE, and Cochrane Library, extracted and analyzed.

RESULTS: A total of 661 placebo-treated patients in 19 trials were included. The overall mortality rate was 34.19% with a median observation time of 160 d (range 21-720 d). Hepatic failure, gastrointestinal bleeding and infection were the three main causes of death, accounting for 55.47%, 21.17% and 7.30% of all deaths, respectively. One-month mortality data about 324 placebo-treated alcoholic hepatitis patients in 10 trials were reported with a pooled mortality rate of 20.37%. The one-month mortality rate of patients with moderate to severe alcoholic hepatitis tended to be higher than that of general patients (22.69% vs 10.93%, \( P < 0.05 \)), whereas no significant difference was observed between the patients from North America or Europe (22.43% vs 18.45%, \( P > 0.05 \)), neither any difference was found between the studies published before and after 1990 (18.18% vs 21.88%, \( P > 0.05 \)).

CONCLUSION: Alcoholic hepatitis is a severe liver disease with a high mortality rate, and hepatic failure, gastrointestinal bleeding and infection are the three main causes of death.

© 2010 Baishideng. All rights reserved.

Key words: Alcoholic hepatitis; Mortality; Placebo

Peer reviewer: Dr. Manfred V Singer, Professor, hc, MD, (Hon. Doct. Mult.), Department of Medicine II, University Hospital of Heidelberg at Mannheim, Theodor-Kutzer-Ufer 1-3, Mannheim, D-68167, Germany

Yu CH, Xu CF, Ye H, Li L, Li YM. Early mortality of alcoholic hepatitis: A review of data from placebo-controlled clinical trials. *World J Gastroenterol* 2010; 16(19): 2435-2439 Available from: URL: http://www.wjgnet.com/1007-9327/full/v16/i19/2435.htm DOI: http://dx.doi.org/10.3748/wjg.v16.i19.2435

INTRODUCTION

Alcohol abuse causes a variety of liver diseases including alcoholic steatosis, alcoholic hepatitis, liver fibrosis and cirrhosis[1,2]. Generally, alcoholic steatosis is a benign lesion with a favorable prognosis if the patient abstains from alcohol use, whereas alcoholic hepatitis, which is observed in approximately 20% of heavy drinkers, is much more serious and requires treatment[3]. With increasing alcohol consumption worldwide, alcoholic liver disease has become a significant global health concern[4].

Alcoholic hepatitis is characterized by the development of hepatocellular necrosis and inflammation in
alcoholic patients. Its pathogenesis is a multifactorial process involving metabolism of alcohol to toxic products, Kupffer cell stimulation by endotoxin and nutritional impairment lead to liver injury and inflammation. The treatment of alcoholic hepatitis is still mostly symptomatic or empirical at best. Abstinence and supportive care are the two critical principles for the treatment of alcoholic hepatitis. Several clinical trials have shown that corticosteroids can improve the short-term survival of patients with severe alcoholic hepatitis. Recent evidence also suggests that inhibiting tumor necrosis factor-alpha release is beneficial for alcoholic hepatitis.

Since most studies on alcoholic hepatitis have focused either on its pathogenesis or on its potential therapies, its natural history has not been clearly defined. One possible explanation for this is that many alcoholic hepatitis patients are treated with available therapies immediately upon its diagnosis. Active therapies may significantly influence its natural progression and it is inappropriate to withdraw the treatment for studying its natural history. An understanding of the progression of alcoholic hepatitis would contribute to its prevention and treatment.

Randomized placebo-controlled clinical trials are considered the gold standard for evaluating the efficacy of medical interventions on the disease. Data from placebo-controlled trials may also provide valuable information about its natural history. Since the use of placebo has very little effect on the progression of alcoholic hepatitis, placebo-treated patients may be the most suitable subjects for studying its natural history. Since a number of randomized placebo-controlled trials are available on evaluating the treatment of alcoholic hepatitis worldwide, it has become feasible to study its natural history by extracting data from these studies.

In this study, we conducted a pooled analysis of data about alcoholic hepatitis patients who were treated with placebo in the eligible randomized placebo-controlled trials, in an attempt to evaluate the early mortality of such patients.

MATERIALS AND METHODS

Systematic literature search

English literature on alcoholic hepatitis patients in randomized placebo-controlled trials may be searched from PubMed (1966 - March 2009), EMBase (1974 - March 2009), and Cochrane Library (2009, Issue 1) by two independent investigators using the search terms “alcoholic hepatitis”, “alcoholic steatohepatitis”, “alcoholic liver disease”, “placebo” and “randomized controlled trial”. Editorial or letter or comment or review was excluded. Reference lists of the retrieved relevant articles were also searched for additional trials.

Study selection

Two investigators independently performed the study selection. Search findings were screened for potentially eligible trials and full-text articles were obtained for their detail evaluation. Disagreements between the two investigators regarding studies included were solved by consensus.

Studies fulfilling the following criteria were included: studies of a randomized placebo-controlled clinical trial in alcoholic hepatitis patients, studies with enrollment, treatment and analysis of patients well-defined, and studies with more than 15 patients involved in the placebo arm, since we believed that they would not generate enough meaningful data to allow quality assessment. Trials were excluded if relevant data were not extractable or if the case-mix included unclassified alcoholic liver disease patients. Alcoholic hepatitis patients in the placebo arms that received basic active treatment with drugs such as steroids were also excluded.

Data extraction and quality assessment

Data extracted from the studies included name of the first author, publication year, study design, location(s), sample size, randomized method, and gender, mean age and disease severity of patients, description of active therapy, duration of therapy, duration of follow-up, mortality data and causes of death. Data extraction was performed by two independent reviewers. Sections of METHODS and RESULTS were coded to blind reviewers to the above information. Primary investigators were contacted if data were incomplete. The methodological quality of studies included was assessed using a validated quality checklist with a maximum score of 32. A score of 12 (38%) or greater was considered to have acceptable quality.

Statistical analysis

Pooled estimate of each variable of interest was calculated and presented as a mean. The cumulative rate of each outcome of interest was calculated in the placebo arm of eligible studies. $\chi^2$ test was used to compare qualitative variables. $P < 0.05$ (2-tailed test) was considered statistically significant.

RESULTS

Description of trials

We identified 892 potentially relevant articles and excluded 845 articles describing studies that obviously did not fulfill the inclusion criteria in this study by reviewing their titles and abstracts. Of the 47 studies selected for full-text review, 19 were excluded because they were not designed as placebo-controlled trials, 3 were excluded because the patients received other active medications, 4 were excluded because less than 15 patients received placebo, 1 was excluded because detailed survival data were not available, and 1 sharing the same placebo with a previous patient was also excluded. Thus, only 19 studies fulfilled the inclusion criteria in this study (Figure 1).

Of these 19 clinical trials, 9 were single center studies, 10 were multi-center studies. A total of 661 patients with a mean age of 46.4 years served as placebo controls. Detailed information and summarized information about the studies included are shown in Tables 1 and 2, respectively.

Pooled mortality

Of the 661 patients, 226 (34.19%) died during a median
Since the observation time was different among the studies included, we did not directly compare the overall mortality rate of alcoholic patients. In subgroup analysis, we compared the one-month mortality rate of alcoholic patients based on the data extracted from 10 studies.

Of the 10 studies selected for comparison, 2 were performed in moderate to severe alcoholic hepatitis patients, 6 in severe alcoholic hepatitis patients, 2 in unclassified alcoholic hepatitis patients. The pooled one-month mortality rate of such patients tended to increase with increasing severity of the disease. The pooled mortality rate of unclassified, moderate to severe and severe alcoholic hepatitis patients was 10.94% (7/64), 20.75% (11/53), and 23.19% (48/207), respectively (Table 2).

Of the 10 studies, 5 were conducted in the United States and 5 in Europe (UK, France, Belgium and Spain) showing a pooled mortality rate of 22.44% (35/156) and 18.45% (31/168), respectively. No significant difference was found in pooled mortality rate between the patients from North America or Europe ($\chi^2 = 0.791, P = 0.409$) (Table 2).

Of the 10 studies, 5 were published before December 31, 1990, showing a pooled total mortality rate of 17.86% (30/168), 5 were published after January 1, 1991, showing a pooled mortality rate of 23.08% (30/168) (Table 2).

**DISCUSSION**

In this study, we extracted data about alcoholic hepatitis patients in randomized placebo-controlled trials and

---

Table 1 Description of studies included in pooled analysis

| Study                  | Country     | Study type    | Severity of alcoholic hepatitis | Placebo size | Mean age (M/F) | Gender | Active therapy | Therapeutic time | Follow-up time | Deaths (1-mo/overall) |
|------------------------|-------------|---------------|---------------------------------|--------------|----------------|--------|----------------|------------------|---------------|----------------------|
| Helman et al[39], 1971 | US          | Single center | Unclassified                    | 17           | 47.7 NA        | NA     | Prednisolone   | 4 wk             | 3 mo           | NA/6                 |
| Blitzer et al[40], 1977| US          | Single center | Unclassified                    | 16           | 48.4 NA        | NA     | Prednisolone   | 26 d             | 9 wk           | NA/5                 |
| Maddrey et al[41], 1978| US          | Single center | Moderate to severe              | 31           | 42.3 23/8      | Prednisolone | 28-32 d       | 4 wk           | 6/6                 |
| Baker et al[42], 1981  | UK          | Single center | Unclassified                    | 25           | 41.0 13/12     | Insulin/glucagon | 3 wk           | 3 wk           | NA/6                 |
| Hallit et al[43], 1982 | UK          | Single center | Severe                          | 36           | 38.9 32/4      | Propylthiouracil | 6 wk           | 8 wk           | 7/7                  |
| Mendenhall et al[44], 1984| US         | Multi-center  | Moderate to severe              | 88           | 50.4 NA        | NA     | Oxandrolone and prednisolone | 1 mo       | 2 yr           | NA/50                |
| Fehér et al[45], 1987  | Hungary     | Multi-center  | Unclassified                    | 33           | 46.0 18/15     | Insulin/glucagon | 3 wk           | 3 wk           | NA/14                |
| Carrithers et al[46], 1989 | UK       | Multi-center  | Severe                          | 31           | 44.4 21/10     | Methylprednisolone | 4 wk           | 4 wk           | 11/11                |
| Trinchet et al[47], 1989 | Belgium  | Multi-center  | Unclassified                    | 34           | 52.0 17/17     | Colchicine    | 6 mo           | 6 mo           | 0/0                  |
| Akriviadis et al[48], 1990 | UK       | Single center | Severe                          | 36           | 46.8 25/11     | Colchicine    | 1 mo           | 4 mo           | 6/8                  |
| Panos et al[49], 1990  | UK          | Single center | Unclassified                    | 51           | 49.3 22/29     | Polyunsaturated phosphatidyl choline | 2 yr      | 2 yr           | NA/20                |
| Bird et al[50], 1991   | UK          | Single center | Severe                          | 43           | 51.0 16/14     | Insulin/glucagon | 3 wk           | 6 mo           | 14/15                |
| Mezey et al[51], 1991  | UK          | Multi-center  | Severe                          | 26           | 43.7 12/14     | Amino acid suppl. | 3 wk           | 23 mo          | 5/16                 |
| Raymond et al[52], 1992 | France  | Multi-center  | Severe                          | 29           | 48.2 9/20      | Prednisolone   | 4 wk           | 6 mo           | NA/16                |
| Trinchet et al[53], 1992 | France  | Multi-center  | Severe                          | 35           | 48.0 17/18     | Insulin/glucagon | 3 wk           | 1 mo           | 5/5                  |
| Bird et al[54], 1998   | UK          | Multi-center  | Unclassified                    | 30           | 51.0 16/14     | Amloidipine   | 4 wk           | 4 wk           | 7/7                  |
| Akriviadis et al[55], 2000 | US       | Single center | Severe                          | 52           | 46.8 40/17     | Pentoxifylline | 4 wk           | 160 d         | NA/24                |
| Mezey et al[56], 2004  | USA and Spain | Multi-center  | Unclassified                    | 26           | 49.0 16/10     | Vitamin E    | 3 mo           | 1 yr           | NA/5                 |
| Boetticher et al[57], 2008 | USA | Multi-center  | Moderate to severe              | 22           | 49.1 17/5     | Etanercept    | 3 wk           | 6 mo           | 5/5                  |

NA: Not available.

---

Figure 1 Schema for literature search and study inclusion.

---

observation time of 160 d (range 21-720 d). Detailed causes of 137 deaths were available from 13 of the studies. Hepatic failure, gastrointestinal bleeding and sepsis were the three main causes of death, accounting for 55.47%, 21.17% and 7.30% of all deaths, respectively. One-month mortality data were available in 10 studies and the pooled mortality rate for these patients was 20.37% (66/324).

**Subgroup analysis**

Since the observation time was different among the
analyzed their mortality, showing that the mortality rate of alcoholic hepatitis patients is positively correlated with the severity of the disease. Our pooled analysis also showed that hepatic failure, gastrointestinal bleeding and infection were the three main causes of early death of alcoholic hepatitis patients, which may be of great importance in clinical practice.

Unlike nonalcoholic hepatitis, a chronic form of liver disease associated with obesity, alcoholic hepatitis is an acute and potentially life-threatening form of liver disease\(^{1,6}\). The cause of its early mortality is not clear since it is difficult to evaluate a sufficient number of such patients without prompt treatment upon diagnosis. In this study, the data about 661 placebo-treated patients extracted from 19 placebo-controlled trials were evaluated, showing that the mortality rate of alcohol hepatitis patients is 34.19% with a pooled one-month mortality rate of 20.37%, which increases with increasing disease severity. These findings suggest that alcoholic hepatitis patients should be treated promptly upon diagnosis.

Recognizing the causes of death in alcoholic hepatitis patients contributes to the treatment of alcoholic hepatitis. Hepatic failure, gastrointestinal bleeding and infection are the three main causes of early death in alcoholic hepatitis patients. Hepatic failure can be prevented by avoiding exposure to certain hepatotoxic drugs, such as acetaminophen, carbon tetrachloride and galactosamine. Corticosteroid therapy is effective against alcoholic hepatitis\(^{3,6}\), but it may result in complications such as gastrointestinal bleeding. It is, therefore, necessary to evaluate the risks and benefits of corticosteroid therapy for alcoholic hepatitis before it is used.

Due to the limited available data, there are some limitations in this study. First, we did not analyze the factors predicating the early mortality rate of alcoholic hepatitis patients since necessary data could not be extracted from the studies included. However, our pooled analysis provided the main causes of death, which may be of importance in clinical practice. Second, we did not clarify whether the mortality rate of alcoholic hepatitis patients varies between males and females. Since females are reported to be more sensitive to alcohol abuse\(^{7}\), it would be of interest to compare mortality rates of both genders. Third, we did not analyze the potential heterogeneity due to the relative small number of placebo patients. We grouped all the patients irrespective of their age, gender, ethnic distinction, or severity of disease. The pooled analysis of all these cases provided a clearer general picture of early mortality rate in a relatively large sample of alcoholic hepatitis patients.

In summary, alcoholic hepatitis is a severe liver disease with a high early mortality, especially among those with moderate to severe alcoholic hepatitis. Hepatic failure, gastrointestinal bleeding and infection are the three main causes of early death in alcoholic hepatitis patients.

### Table 2  Comparison of pooled one-month mortality by different variables

| Severity of disease         | Studies (n) | Placebo-treated patients (n) | Gender (M/F) | One-month death (n) | One-month mortality rate (%) | χ²  | P value |
|-----------------------------|-------------|-------------------------------|--------------|---------------------|------------------------------|------|---------|
| Unclassified                | 2           | 64                            | 33/31        | 7                   | 10.94                        | 4.375| 0.038   |
| Moderate to severe          | 8           | 260                           | 171/89       | 59                  | 22.69                        |      |         |
| Geographical area(s)        |             |                               |              |                     |                              |      |         |
| US                          | 5           | 156                           | 119/37       | 35                  | 22.44                        | 0.791| 0.409   |
| Europe                      | 5           | 168                           | 85/83        | 31                  | 18.45                        |      |         |
| Publication year            |             |                               |              |                     |                              |      |         |
| Before 1990                 | 5           | 168                           | 118/50       | 30                  | 17.86                        | 1.359| 0.271   |
| After 1991                  | 5           | 156                           | 86/70        | 36                  | 23.08                        |      |         |

### COMMENTS

#### Background

Alcoholic hepatitis is a potentially life-threatening complication of alcohol use, but its natural history has not been clarified so far.

#### Research frontiers

This study investigated the early mortality of placebo-treated alcoholic hepatitis patients.

#### Innovations and breakthroughs

This study has confirmed that alcoholic hepatitis is a severe liver disease with a high early mortality, especially among those with moderate to severe disease.

#### Applications

The results of this study suggest that hepatic failure, gastrointestinal bleeding and infection should be treated in order to prevent early death of alcoholic hepatitis patients.

#### Terminology

Alcoholic hepatitis is a disease resulting from hepatocellular necrosis and inflammation in alcoholic patients. Its pathogenesis is a multifactorial process involving metabolism of alcohol to toxic products. Kupffer cell stimulation by endotoxin and nutritional impairment lead to liver injury and inflammation, etc.

#### Peer review

This is an interesting review of data concerning the early mortality of alcoholic hepatitis. The authors critically discussed the limitation of their survey.

### REFERENCES

1. Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004; 24: 217-232
2. Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. Alcohol Res Health 2003; 27: 209-219
3. Menon KV, Gores GJ, Shah VH. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc 2001; 76: 1021-1029
4. Li YM. Alcoholism and alcoholic liver disease: focusing on epidemiological investigation in Asia. Hepatobiliary Pancreat Dis Int 2005; 4: 170-172
5. Rehn J, Room R, Monteiro M, Gmel G, Graham K, Rehn N, Sempos CT, Jernigan D. Alcohol as a risk factor for global burden of disease. Eur Addict Res 2003; 9: 157-164
6. Mathurin P. Corticosteroids for alcoholic hepatitis--what’s next? J Hepatol 2005; 43: 526-533
7. Haber PS, Warner R, Seth D, Gorrell MD, McCaughan GW.
Pathogenesis and management of alcoholic hepatitis. J Gastroenterol Hepatol 2003; 18: 1332-1344

8 Mathurin P, Mendenhall CL, Cantharis RL Jr, Ramond MJ, Maddrey WC, Gazstide P, Rueff BH, Navas S, Chaput JC, Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo-controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 480-487

9 Akrividias E, Botta R, Briggs W, Han S, Reynolds T, Shkild O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648

10 Greenfield S, Kravitz R, Duan N, Kaplan SH. Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med 2007; 120: 53-59

11 Hrubjartsson A, Gattsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594-1602

12 Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377-384

13 Harrison RA, Siminowski K, Vethayyanagam A, Majumdar SR. Osteoporosis-related kyphosis and impairments in pulmonary function: a systematic review. J Bone Miner Res 2007; 22: 447-457

14 Spahr L, Rubbia-Brandt L, Frossard JL, Giovista E, Rouge Prach AT, McMahon AD, Forrest JA, Mills PR, Prince M, Bassendine M, Hudson M, James O, Simon FR, Pope CE 2nd, Volwiler W, Fenster Gas.

15 Helman RA. Early mortality of alcoholic hepatitis. Ann Intern Med 1971; 74: 311-321

16 Blitzer BL, Mutchnick MG, Joshi PH, Phillips MM, Fessel JM, Conn HO. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977; 22: 477-484

17 Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezy E, White RJ Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-199

18 Baker AL, Jaspal JB, Haines NW, Hatfield GE, Krager PS, Schneider JF. A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients. Gastroenterology 1981; 80: 1410-1414

19 Hallé P, Paré P, Kaptein E, Kanel G, Redeker AG, Reynolds TB. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology 1982; 82: 925-931

20 Mendenhall CL, Anderson S, García-Pont P, Goldberg S, Kiernan T, Seeff LB, Sorrell M, Tamburro C, Weesner R, Zetterman R. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984; 311: 1464-1470

21 Fehér J, Comides A, Romány A, Károlyi L, Szalay L, Gögl A, Picazo J. A prospective multicenter study of insulin and glucagon infusion therapy in acute alcoholic hepatitis. J Hepatol 1987; 5: 224-231

22 Cañí˘thars RL Jr, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989; 110: 685-690

23 Trinchet JC, Beaufrand M, Callard P, Hartmann DJ, Gotheil C, Nusgens BV, Lapiere CM, Ferrier JP. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterology Clin Biol 1989; 13: 551-555

24 Akrividias EA, Steinidtl H, Pinto PC, Fong TL, Kanel G, Reynolds TB, Gupta S. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology 1990; 99: 811-818

25 Pappos MZ, Polson R, Johnson R, Portmann B, Williams R. Polyunsaturated phosphatidylcholine for acute alcoholic hepatitis: a double-blinded, randomized, placebo-controlled trial. Eur J Gastroenterol Hepatol 1990; 2: 351-355

26 Bird G, Lui JY, Koskinas J, Wicks C, Williams R. Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial. Hepatology 1991; 14: 1097-1101

27 Mezy E, Caballeria J, Mitchell MC, Parés A, Herlong HF, Rodés J. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: a randomized controlled trial. Hepatology 1991; 14: 1090-1096

28 Trinchet JC, Balkau B, Poupen RE, Heintzmann F, Callard P, Gothiel C, Grange JD, Vetter V, Pauwels A, Labadie H. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 1992; 15: 76-81

29 Bird GL, Prach AT, McMahon AD, Forrest JA, Mills PR, Danesh BJ. Randomised controlled double-blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. J Hepatol 1998; 28: 194-198

30 Mezy E, Potter JJ, Rennie-Tankersley L, Caballeria J, Pares A. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 2004; 40: 40-46

31 Boetticher NC, Peine CJ, Kuef P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1533-1540

32 Rambaldi A, Sacanato HH, Christensen E, Thorlund K, Wetterslev J. Systematic review: glucocorticosteroids for alcoholic hepatitis--A Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized controlled trials. Aliment Pharmacol Ther 2008; 27: 1167-1178